Abstract: Objective To investigate the clinical value of serum ceruloplasmin in the diagnosis and prognosis of
hepatitis B virus carriers with gynecologic tumor. Methods Total of 90 HBV carriers with gynecologic tumor
in Beijing Ditan Hospital, Capital Medical University from June 1, 2013 to July 3, 2016 were selected as cancer
group (including 42 cases with benign tumors and 48 cases with malignant tumors) and another 45 female
HBV carriers were selected as control group. Immunohistochemical rate nephelometer technique was used to
assess the levels of serum ceruloplasmin. The core-fucosylation ratio of 138 site and 397 site were also detected.
Results The serum level of ceruloplasmin in benign group and patients underwent radical resection of malignant
tumor had no statistical differences compared with that in control group (t = 0.771, 0.534; P = 0.586, 0.711). The
serum levels of ceruloplasmin in patients with malignant tumor were significantly higher than those of patients
with benign tumor and controls (t = 3.259, 1.365; P = 0.013, 0.022). After radical correction, 6 out of 20 cases
were found tumor recurred, whose serum ceruloplasmin levels increased significantly (t = 3.255, P = 0.015).
The ceruloplasmin core-fucosylation ratio of 138 site and 397 site of malignant tumor group were significantly
higher than those of benign group and controls (138 site: t = 3.567, 4.556, P = 0.023, 0.014; 397 site: t = 4.598,
4.620, P = 0.013, 0.011). Conclusions Serum ceruloplasmin level has a reliable clinical value on the differential
diagnosis of gynecological oncological diseases and has great significance on the follow-up strategy of cancer.